key: cord-0747043-u5w8wv80
authors: Svyatchenko, Victor A.; Nikonov, Sergey D.; Mayorov, Alexander P.; Gelfond, Mark L.; Loktev, Valery B.
title: Antiviral Photodynamic Therapy: Inactivation and Inhibition of SARS-CoV-2 In Vitro Using Methylene Blue and Radahlorin
date: 2020-11-26
journal: Photodiagnosis Photodyn Ther
DOI: 10.1016/j.pdpdt.2020.102112
sha: 174eb0fe5350ffb32b96cb4003e2d235333b380c
doc_id: 747043
cord_uid: u5w8wv80

INTRODUCTION: Recently, the COVID-19 pandemic has spread globally, necessitating the development of new methods for its prevention and treatment. The purpose of this study was to evaluate the antiviral activity of photodynamic therapy (PDT) against SARS-CoV-2 in vitro. METHODS: Vero E6 cells and SARS-CoV-2 isolated in Russia were used for PDT with methylene blue (MB) and Radahlorin. A continuous laser with wavelength λ = 662 nm in doses of 16 J/cm(2) and 40 J/cm(2) laser irradiation was used for PDT of a viral suspension and SARS-CoV-2-infected cells. The direct cytopathogenic effect of SARS-CoV-2 was evaluated via light microscopy to calculate the TCID(50) in the samples and perform statistical analysis. RESULTS: Viral suspensions of SARS-CoV-2 that had a TCID(50) greater than 10(3) were inactivated by PDT in the presence of MB and Radahlorin. Vero E6 cells were protected from 10(4) TCID(50) of SARS-CoV-2 by PDT post infection. The range of protective concentrations was 1.0–10.0 µg/ml and 0.5–5.0 µg/ml for MB and Radahlorin, respectively. Additionally, it was found that MB and Radahlorin also possess significant antiviral activity even without PDT. The 50% inhibitory concentration (IC(50)) against 10(2) TCID(50) of SARS-CoV-2 was found to be 0.22 and 0.33 µg/ml with the addition of MB and Radahlorin, respectively, to cells concomitantly with virus, whereas in the case of applying the photosensitizers at 3.5 hours post infection, the IC(50) was 0.6 and 2.0 µg/ml for MB and Radahlorin, respectively. CONCLUSION: PDT shows high antiviral activity against SARS-CoV-2 when combined with MB and Radahlorin in vitro.

Over the past two decades, different coronavirus species have caused three severe human disease outbreaks characterized by respiratory tract lesions [1] . The COVID-19 pandemic, caused by a new coronavirus, originated in Wuhan, China, in 2019 and has spread rapidly across the world.

Modern sequencing techniques have made it possible to decode viral genomes and rapidly carry out their taxonomic identification [2] . The virus was classified as a novel coronavirus and named SARS-CoV-2, belonging to the family Coronaviridae of the order Nidovirales. As of 26 October, SARS-CoV-2 has circulated in more than 215 countries, with 43,381,914446 registered cases of human infection and 1,159,667 deaths [3] . The development of the COVID-19 pandemic was characterized, especially initially, by the absence of antiviral drugs and vaccines to prevent and treat the infection. The high infection rate of SARS-CoV-2 is also associated with severe clinical problems, such as the development of viral bilateral pneumonia and pronounced immunopathological changes, causing high mortality, especially among elderly individuals and in patients suffering from comorbidities [4] .

The severity of COVID-19 urgently requires the development of new methods for the prevention and treatment of the disease. One of these approaches can be antiviral photodynamic therapy [5] . Previously, the effectiveness of PDT in the inactivation of mammalian viruses has been demonstrated for several RNA-and DNA-containing viruses. Some of these viruses include herpesviruses; human immunodeficiency virus; hepatitis A, B, and C viruses; human parvovirus B19; human cytomegalovirus; adenoviruses; and enteroviruses. It has also been observed that enveloped viruses are more sensitive to PDT than nonenveloped viruses [6] [7] [8] . Currently, PDT is widely used to inactivate viruses in different biological fluids, for example, in blood tissue samples.

PDT is also highly effective for the treatment of surface viral lesions on the skin and mucous membranes [9, 10] .

Many photosensitizers (PSs) made from various chemical compounds are used for PDT [5] ; among these are methylene blue (MB) and Radahlorin, which are categorized as medicinal drugs in J o u r n a l P r e -p r o o f the Russian Federation. MB has long been used against various infectious agents, especially in urology [11] [12] . MB is a phenothiazine compound that possesses photosensitizer properties.

Radahlorin contains 70-90% chlorin E6, derived from the chlorophyll of microalgae belonging to the genus Spirulina. Radahlorin is a second-generation PS with a maximum absorption of light energy in the red spectrum at a wavelength of 662 nm. It is widely used for treating precancerous virus-associated cervical intraepithelial neoplasms as well as cancerous lesions of the skin and some bacterial infections [13] .

Our aim in this study was to evaluate the effectiveness of PDT in the inactivation of SARS-CoV-2 viral suspensions along with the treatment of SARS-CoV-2-infected green monkey kidney cells using photosensitizers such as MB and Radahlorin as medicinal drugs.

The viral strain RP/2020 SARS-CoV-2 was isolated in Vero E6 cells in early 2020 in Russia from a patient suffering from COVID-19. The virus was cultivated in a monolayer of the monkey kidney cells, Vero E6 (SRC VB "Vector"), using Minimum Essential Medium (MEM) supplemented with 5% fetal bovine serum and 40 µg/ml gentamicin sulfate. The infectious activities of the viral suspensions were determined using the 50% tissue culture infectious dose (TCID50) method [14] .

Light exposure for the viral suspension and the infected cell culture monolayers was carried out by using continuous monoposition radiation generated using a Lahta Milon semiconductor laser generator with a wavelength λ=662 nm. This step was carried out in a light box containing plastic To study the direct inactivation of SARS-CoV-2 in vitro by PDT with MB and Radahlorin, 0.2 ml of viral suspensions containing 10 3 50% tissue culture infection doses (TCID50) of SARS-CoV-2 was transferred to 1.5 ml microtubes, and equal volumes of the PSs in the culture medium were added. Immediately after addition, each sample was treated with λ = 662 nm laser radiation with 16 J/cm 2 or 40 J/cm 2 light energy, and the Vero E6 cell monolayer cultured in microwells was immediately infected to analyze the effects on the virus.

To assess the photodynamic effects on SARS-CoV-2 replication within Vero E6 cells, subconfluent monolayers in T25 (25 cm 2 ) plastic cell culture flasks were infected with 10 2 to 10 5 TCID50 of the viral mixture. Then, the PSs were added. This addition was followed by light treatment of the culture vials with laser light at an energy density of 40 J/cm 2 and using 350 mW of output power. Samples containing the added PSs without laser treatment, samples undergoing laser irradiation without the addition of PS, and samples with neither the PSs nor light treatment were used as the controls.

The antiviral effects of PDT on SARS-CoV-2-containing suspensions were determined 48 hours post infection (p.i.). In this regard, monolayers of infected Vero E6 cells were incubated in 96-well cell plastic plates at 37°C in a CO2 incubator in total darkness. At 2 days p.i., virus-induced CPE was evaluated by microscopy and then confirmed by a formazan-based MTT [3-(4,5dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide] cell viability assay [15] .

The antiviral activity of the PSs is expressed as the IC50, defined as the compound concentration producing 50% inhibition of virus replication, as estimated by microscopic scoring of J o u r n a l P r e -p r o o f 6 the CPE and by measuring cell viability in the formazan-based MTT assay [16] . Briefly, cells were seeded in a 96-well flat-bottom microtiter plate at a density of 5 × 10 4 cells/well; after 24 hours of incubation, cell monolayers were infected with SARS-CoV-2 (10 2 TCID50/well), and dilutions of PSs were added to the cells immediately or at 3.5 hours p.i.; after 48 hours of incubation, the culture medium was replaced with fresh medium; 10 μL of MTT working solution (5 mg/mL in phosphate buffer solution) was added to each well, and the plate was incubated for 4 hours at 37°C; the medium was then aspirated, and the formed formazan crystals were solubilized by adding 50 μL of DMSO per well for 30 min at 37°C; the intensity of the optical density was quantified using an ELISA plate reader at 540 nm. Cytotoxicity is expressed as the CC50, the compound concentration producing a 50% cytotoxic effect estimated by the MTT cell viability assay.

Statistical data processing was conducted using the statistical program STATISTICA 12 (StatSoft Inc., USA). Statistical significance was determined at p < 0.05.

All experiments involving any infectious viral materials were conducted in a biosafety level-3 laboratory after obtaining all the national certificates and permissions required for studying SARS-CoV-2.

The PDT against the 

To assess the effect of photodynamic therapy on SARS-CoV-2 replication within Vero E6 cells, subconfluent monolayers in cell culture flasks were infected with 10 2 to 10 5 TCID50 of the viral mixture, followed by the addition of PSs and PDT. Figure 2 

A study of the antiviral activity of PSs was conducted in the absence of light exposure. The antiviral activity of PSs was determined in two variants. In the first variant, Vero E6 monolayers were infected with 10 2 TCID50 of SARS-CoV-2, and PSs were immediately added to the cells. In the second, PSs were added to infected cells 3.5 hours post infection. The results demonstrated that the PSs exerted significant antiviral activity in both cases ( Table 1 ). The IC50 (50% effective inhibitory concentration) was 0.22 µg/ml for MB, and the therapeutic index (the ratio of CC50 to IC50) was more than 450.

Interestingly, the antiviral activity of MB and Radahlorin was also detected when PSs were Their antiviral activities against SARS-CoV-2 were at least 100 times lower than those of MB and Radahlorin.

A hypothesis about the potential efficacy of PDT against SARS-CoV-2 was formulated relatively recently, and a short report on the application of PDT in humans has also been published [18, 19] . We attempted to investigate the possibility of using PDT to inactivate SARS-CoV-2 and inhibit its replication within a monolayer of virus-sensitive green monkey kidney cells. The mechanism of the antiviral activity of PDT against SARS CoV-2 still needs to be fully J o u r n a l P r e -p r o o f clarified [5] . Typically, the antiviral effect is associated with the interaction of PSs with viral or cellular molecules. PSs are activated by light and then transfer energy to other molecules. Oxygen usually acts as an energy acceptor by attaining a singlet form and triggering a cascade of freeradical reactions that damage the biological structures of viruses as well as rapidly proliferating and malignant cells. Additionally, there is also recent evidence of possible in vitro antiviral activity for MB even in the absence of light-induced activation, as MB showed virucidal activity at low micromolar concentrations when incubated with SARS-CoV-2 [20] . Its ability to inhibit the proteinprotein interaction of the SARS-CoV-2 spike protein and its receptor ACE2, which is the first critical step initiating viral attachment and entry, could be a mechanism of action contributing to such activity.

It is important to note that SARS CoV-2 is a fast-replicating coronavirus that usually causes regions of the spectrum, is also well known [22] . This suggests that PDT may become a highly effective method for the prevention and treatment of COVID-19, especially in the early stages of the disease. A fundamental advantage of this approach is that it can be used during a primary outbreak of coronavirus infection to cease the outbreak and prevent contact infection, particularly in asymptomatic patients. Vorozhtsov Novosibirsk Institute of Organic Chemistry of the SB RAS) as potential inhibitors for viral RNA-dependent RNA polymerase of influenza virus. *the CC50 value [17] . NT -not tested.

The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century

Emerging coronaviruses: Genome structure, replication, and pathogenesis

COVID-19 coronavirus pandemic

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges

Photodynamic inactivation of mammalian viruses and bacteriophages

New phthalocynanines for photodynamic virus inactivation in red blood cell concentrates

Photodynamic inactivation of enveloped viruses by buckminsterfullerene

Photodynamic therapy: A new antimicrobial approach to infectious disease? Photoch

Photodynamic inactivation of herpes simplex: Report of a clinical trial

The photodynamic action of methylene blue on certain viruses

Methylene bluemediated photodynamic inactivation as a novel disinfectant of enterovirus 71

In vitro photodynamic inactivation of Mycobacterium tuberculosis by Radahlorin. Tuberculosis and Lung Diseases

Antigenic relationships of alphaviruses by a simple micro-culture cross-neutralization method

Towards an optimized MTT assay

In vitro cytotoxicity of nitroxyl radicals J o u r n a l P r e -p r o o f with respect to tumor and diploid human cells and estimation of their antiviral activity

Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors

Antimicrobial Photodynamic Therapy in the Control of COVID-19

COVID-19: Beyond the virus. The use of Photodynamic Therapy for the Treatment of Infections in the Respiratory Tract

Methylene blue has a potent antiviral activity against SARS-CoV-2 in the absence of UV-activation in vitro

Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV

Review of Chemotherapy and Photodynamic Therapy for Lung Cancer Treatment

× 10 5 cells in each well) were infected with a mixture containing 10 3

TCID50 of SARS-CoV-2, with the addition of MB at a concentration of 10.0 µg/ml, following laser

3 TCID50 of SARS-CoV-2, 10.0 µg/ml MB, 100 sec

3 TCID50 of SARS-CoV-2, 10.0 µg/ml MB, without laser treatment

3 TCID50 of SARS-CoV-2, 1.0 µg/ml MB, 40 sec

10 3 TCID50 of SARS-CoV-2, 1.0 µg/ml MB, 100 sec

3 TCID50 of SARS-CoV-2, 1.0 µg/ml MB, without laser treatment

3 TCID50 of SARS-CoV-2, 5.0 µg/ml Radahlorin, 40 sec

3 TCID50 of SARS-CoV-2, 5.0 µg/ml Radahlorin, 100 sec

3 TCID50 of SARS-CoV-2, 5.0 µg/ml Radahlorin, without laser treatment; 10. 10 3 TCID50 of SARS-CoV-2, 0.5 µg/ml Radahlorin, 40 sec

10 3 TCID50 of SARS-CoV-2, 0.5 µg/ml Radahlorin, 100 sec, 40 J/cm 2 ; 12. 10 3 TCID50 of SARS-CoV-2, 0.5 µg/ml Radahlorin, without laser treatment; 13. 10 3 TCID50 of SARS-CoV-2, laser irradiation, 40 sec

10 3 TCID50 of SARS-CoV-2, laser irradiation, 100 sec

10 3 TCID50 of SARS-CoV-2, without laser treatment

The research was supported by the Russian Federal Service for Consumer Protection and HumanWelfare.

The authors state that there is no conflict of interest.

This article does not describe any studies involving humans or animals as the test subjects.J o u r n a l P r e -p r o o f